Utama › Mieloma Pelbagai › North Carolina › Durham
Kajian klinikal Mieloma Pelbagai di Durham, NC
37 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Durham (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Mengambil pesertaFasa 3
- Research Site, Chapel Hill · 10 mi jauh
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Mengambil pesertaFasa 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mi jauh
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Mengambil pesertaFasa 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Mengambil pesertaFasa 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mi jauh
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Mengambil pesertaFasa 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi jauh
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Mengambil pesertaFasa 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mi jauh
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Mengambil pesertaFasa 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi jauh
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Mengambil pesertaFasa 1/2
- GSK Investigational Site, Chapel Hill · 10 mi jauh
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Mengambil pesertaFasa 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Mengambil pesertaFasa 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mi jauh
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Mengambil peserta
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi jauh
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Mengambil pesertaFasa 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mi jauh
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Mengambil pesertaFasa 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mi jauh
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Mengambil pesertaFasa 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mi jauh
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Mengambil pesertaFasa 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauh
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Mengambil pesertaFasa 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi jauh
Registry of Older Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauh
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Mengambil pesertaFasa 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Mengambil pesertaFasa 2
- University of North Carolina, Chapel Hill · 10 mi jauh
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Mengambil pesertaFasa 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauh
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mi jauh
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Mengambil pesertaFasa 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mi jauh
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Mengambil pesertaFasa 1
- University of North Carolina, Chapel Hill · 10 mi jauh
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Mengambil pesertaFasa 1
- University of North Carolina, Chapel Hill · 10 mi jauh
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Mengambil pesertaFasa 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mi jauh
Registry for Adults With Plasma Cell Disorders (PCD's)
Mengambil pesertaKajian pemerhatian
- North Carolina Cancer Hospital, Chapel Hill · 10 mi jauh
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Mengambil pesertaKajian pemerhatian
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauh
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Duke University Health System (DUHS), Durham
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA41 kajian
- Houston, TX38 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- St. Louis, MO24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Chicago, IL22 kajian
- Seattle, WA22 kajian
Kajian lain di Durham
- Kanser Payudara63 kajian
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil39 kajian
- Kanser Metastatik33 kajian
- Leukemia Mieloid Akut33 kajian
- Kanser Paru-paru32 kajian
- Kanser Prostat32 kajian
- Kanser Kolorektal28 kajian
- Leukemia Limfositik Kronik27 kajian
- Kanser Ovari27 kajian
- Kegagalan Jantung26 kajian
- Kanser Pankreas24 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.